Elanco Animal Health (NYSE:ELAN) Releases FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 1.170-1.200 for the period, compared to the consensus EPS estimate of 1.130. The company issued revenue guidance of $5.2 billion, compared to the consensus revenue estimate of $5.1 billion. Elanco Animal Health also updated its Q4 2026 guidance to 0.160-0.190 EPS.

Wall Street Analysts Forecast Growth

ELAN has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on shares of Elanco Animal Health in a report on Friday, October 16th. They set a “buy” rating and a $32.00 price objective for the company. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. UBS Group lifted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, September 30th. Finally, Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and decreased their price target for the company from $31.00 to $24.00 in a report on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average target price of $29.33.

Elanco Animal Health Trading Up 6.6%

Shares of Elanco Animal Health stock traded up $1.57 during trading hours on Friday, hitting $25.25. The company’s stock had a trading volume of 3,328,430 shares, compared to its average volume of 5,580,573. The company has a market capitalization of $12.62 billion, a PE ratio of -61.59, a price-to-earnings-growth ratio of 2.25 and a beta of 1.73. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The stock has a 50 day moving average of $23.11 and a 200 day moving average of $23.82. Elanco Animal Health has a 12 month low of $19.40 and a 12 month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the previous year, the business posted $0.19 EPS. Elanco Animal Health’s revenue for the quarter was up 11.3% on a year-over-year basis. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Analysts predict that Elanco Animal Health will post 1.13 earnings per share for the current year.

Insider Activity at Elanco Animal Health

In related news, Director Lawrence Kurzius purchased 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The stock was bought at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael J. Harrington purchased 5,000 shares of Elanco Animal Health stock in a transaction dated Wednesday, August 12th. The stock was bought at an average price of $21.82 per share, with a total value of $109,100.00. Following the acquisition, the director directly owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. This trade represents a 3.95% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 48,998 shares of company stock valued at $1,139,373. Corporate insiders own 1.14% of the company’s stock.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS of $0.27 topped the $0.20 consensus estimate, and revenue of $1.265 billion exceeded expectations of about $1.21 billion. Revenue rose 11% year over year, with 9% organic constant-currency growth. Elanco third-quarter results
• Positive Sentiment: Elanco raised 2026 adjusted EPS guidance to $1.17–$1.20, above the $1.13 consensus, and lifted revenue guidance to $5.155–$5.18 billion versus approximately $5.1 billion expected. It also increased its innovation revenue target and improved its year-end net leverage target to about 2.9x adjusted EBITDA. Elanco third-quarter results
• Positive Sentiment: Company survey results suggest resilient consumer demand: 93% of surveyed pet owners maintained or increased pet spending over the prior three months, supporting the outlook for pet-health products. Elanco consumer research
• Neutral Sentiment: Fourth-quarter revenue guidance of $1.2 billion matches consensus. EPS guidance of $0.16–$0.19 has a midpoint of $0.175, just below the $0.18 estimate, though the range includes consensus. Elanco third-quarter results

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.